Clinical Trial Update: Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial REVISE-Diab obesity randomises Endobarrier alone versus Endobarrier plus an incretin analogue in people with Type 2 diabetes and obesity.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• EndoBarrier (duodenal-jejunal bypass liner)
• Incretin analogue

Snippet

Sponsor: Sandwell & West Birmingham Hospitals NHS Trust | Conditions: Type 2 Diabetes, Obesity | Phase 4 | Status: UNKNOWN